Punch & Associates Investment Management Inc. Takes Position in Viemed Healthcare, Inc. $VMD

Punch & Associates Investment Management Inc. purchased a new stake in shares of Viemed Healthcare, Inc. (NASDAQ:VMDFree Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 533,466 shares of the company’s stock, valued at approximately $6,082,000.

A number of other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in Viemed Healthcare in the first quarter worth $90,000. Jane Street Group LLC bought a new position in Viemed Healthcare during the 1st quarter valued at about $394,000. Geode Capital Management LLC grew its holdings in Viemed Healthcare by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 798,515 shares of the company’s stock valued at $5,519,000 after purchasing an additional 15,353 shares during the last quarter. JPMorgan Chase & Co. raised its position in Viemed Healthcare by 3.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 174,551 shares of the company’s stock worth $1,206,000 after purchasing an additional 5,099 shares during the period. Finally, Rhumbline Advisers lifted its stake in Viemed Healthcare by 9.0% in the second quarter. Rhumbline Advisers now owns 51,456 shares of the company’s stock worth $356,000 after purchasing an additional 4,228 shares during the last quarter. 74.24% of the stock is currently owned by institutional investors.

Insider Transactions at Viemed Healthcare

In other news, insider William Frazier sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $11.72, for a total value of $117,200.00. Following the completion of the sale, the insider owned 73,214 shares in the company, valued at approximately $858,068.08. The trade was a 12.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Timothy Smokoff sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total transaction of $230,000.00. Following the transaction, the director owned 75,518 shares in the company, valued at approximately $868,457. This represents a 20.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 20.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on VMD. Freedom Capital lowered Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Wall Street Zen lowered Viemed Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Barrington Research started coverage on Viemed Healthcare in a report on Monday. They set an “outperform” rating and a $14.00 price objective for the company. Finally, Weiss Ratings cut Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 17th. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Viemed Healthcare has an average rating of “Hold” and an average target price of $14.00.

Check Out Our Latest Research Report on VMD

Viemed Healthcare Price Performance

VMD opened at $9.33 on Thursday. The company has a market capitalization of $355.38 million, a price-to-earnings ratio of 25.92, a PEG ratio of 2.25 and a beta of 1.10. The company has a current ratio of 1.13, a quick ratio of 1.02 and a debt-to-equity ratio of 0.04. Viemed Healthcare, Inc. has a 12-month low of $6.05 and a 12-month high of $12.61. The business’s fifty day simple moving average is $10.90 and its 200-day simple moving average is $9.89.

Viemed Healthcare (NASDAQ:VMDGet Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. The firm had revenue of $78.10 million during the quarter, compared to the consensus estimate of $78.00 million. On average, equities research analysts anticipate that Viemed Healthcare, Inc. will post 0.41 earnings per share for the current fiscal year.

Viemed Healthcare Profile

(Free Report)

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.

Read More

Want to see what other hedge funds are holding VMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viemed Healthcare, Inc. (NASDAQ:VMDFree Report).

Institutional Ownership by Quarter for Viemed Healthcare (NASDAQ:VMD)

Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.